ExpreS2ion and Abivax enter agreement to develop Ebola treatment

Denmark-based ExpreS2ion Biotechnology and Abivax, a French biotechnology company, have entered into a service and commercial licensing agreement under which the companies will collaborate in their development of a treatment for Ebola.

The companies will develop a process for the production of an Ebola antigen, required for the Ebola treatment, known as ABX544.

The preclinical work is expected to start in 2017 and the licensing agreement is scheduled to be signed within three months.

Financial terms of the agreement were not disclosed.